Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

LENZ Therapeutics (LENZ) Depreciation and Depletion (2022 - 2023)

LENZ Therapeutics (LENZ) has disclosed Depreciation and Depletion for 2 consecutive years, with $800000.0 as the latest value for Q3 2023.

Quarterly Depreciation and Depletion rose 14.29% to $800000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Sep 2023, changed N/A year-over-year, with the annual reading at $2.4 million for FY2023, 0.0% changed from the prior year.
Depreciation and Depletion for Q3 2023 was $800000.0 at LENZ Therapeutics, roughly flat from $800000.0 in the prior quarter.
The five-year high for Depreciation and Depletion was $800000.0 in Q2 2023, with the low at $400000.0 in Q1 2022.